ID1 and lymphangioleiomyomatosis: Importantly, since all LAM lesions revealed ID1 positivity, compounds targeting this factor could potentially exhibit therapeutic benefit in LAM; however, the compounds tested in this study did not show specificity in Tsc2-deficient cells or the expected molecular down-regulation [56–59], which would discourage their use in combination with rapamycin or rapalogs.